Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study

Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on March 29 the final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® in IgA nephropathy (IgAN). The company reported that Fabhalta exhibited a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate slope compared with placebo, which is a key marker of kidney function.

The study showed that Fabhalta lowered the likelihood of progression to kidney failure by 43%, with 40.7% of patients on Fabhalta exhibiting sustained reduction of protein in urine over two years. Novartis AG (NYSE:NVS) also stated that Fabhalta consistently showed potential to preserve kidney function in IgAN by showing a slowing of disease progression. Management added that Fabhalta was granted priority review by the FDA for traditional approval.

Vlado Perkovic, MD, Professor of Medicine and Provost, University of New South Wales, and Steering Committee Co‑Chair of the APPLAUSE‑IgAN study, stated that the results are significant because they demonstrate Fabhalta’s ability to “reduce the risk of disease progression, help preserve kidney health, and address outcomes associated with long-term disease burden.”

Headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a range of healthcare and pharmaceutical products, and is also involved in immuno-oncology research. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.